PDE4 Activator Compounds for cAMP Signaling Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for structurally distinct small molecule activators of PDE4 long forms for therapeutic use, as existing activators have not been reported in clinical development, and current methods lack effective solutions for disorders related to excessive intracellular cAMP signaling.
Innovation Solution
Development of compounds of specific formulas, such as Formula A, B, C, and D, which are small molecules that selectively activate PDE4 long forms, thereby reducing cAMP-driven responses, and are suitable for use in treating various diseases mediated by excessive intracellular cAMP signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule activators of PDE4 long forms are developed for therapeutic use, then disorders requiring reduction of cAMP signaling can be treated, but no small molecule activators have been reported in clinical development yet
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular structures (different R groups, ring systems, and substituents in Formulas A-D) to optimize PDE4 activation while maintaining selectivity. This structural parameter optimization enables the compounds to effectively reduce cAMP signaling in disease models, addressing the therapeutic effectiveness requirement while establishing a foundation for clinical development
2Reliability
If compounds are designed to selectively activate PDE4 long forms, then cAMP-driven responses are reduced, but structural distinctness from existing activators is required
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core heterocyclic system (Formula A-D) with specific R1, R2, R3, R4, R5, and R6 substituents. This segmented approach allows independent optimization of PDE4 binding interactions while maintaining overall structural distinctness from existing activators, achieving both selectivity and structural novelty
Solution Approach 2:
The compounds represent composite molecular structures combining heterocyclic cores with various substituent groups (aromatic rings, alkyl chains, heteroatoms). This composite design creates structurally distinct molecules that achieve selective PDE4 long form activation through multiple simultaneous interactions, balancing selectivity with manageable structural complexity
3Reliability
If PDE4 activation is used to reduce cAMP signaling, then disorders like ADPKD and hyperparathyroidism can be treated, but excessive intracellular cAMP signaling must be targeted
Solution Approach 1:
The patent converts the harmful effect of excessive cAMP signaling into a therapeutic benefit by activating PDE4 enzymes to degrade cAMP. The compounds achieve this by binding to and activating PDE4 long forms, which hydrolyze cAMP to 5'-AMP, thereby reducing pathological cAMP levels in diseases like ADPKD and hyperparathyroidism while sparing normal physiological functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively activate PDE4 long forms, demonstrating selectivity over short forms, reducing cAMP-driven cyst formation in ADPKD models and suppressing urinary cAMP levels in hyperparathyroidism, providing therapeutic benefits for multiple disorders.
Implementation Method 1
compounds as defined herein, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms)
Implementation Method 2
PDE4 enzymes inactivate cAMP, thereby terminating its signalling, by hydrolysing cAMP to 5′-AMP
Data Source
AI summary
The present invention relates to compounds of Formulas A-D, I-IV and Z, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).